Purpose of review Recent advances in our understanding of cancer immunology resulted in the development of promising therapeutic agents for either nonantigen-specific immunotherapy, for example, monoclonal antibodies targeting immune checkpoints on the T-cell lymphocyte, and antigen-specific immunotherapy or vaccination. Here, we review the recently reported results from randomized controlled trials (RCTs) with the latter approach.
INTRODUCTION
Lung cancer is one of the most prevalent malignancies worldwide and the leading cause of cancer-related death [1] . Most cases are non-smallcell lung cancer (NSCLC). Progress has been made in the curative-intent multimodality treatment of early and locally advanced stage patients, but even then relapse and lung cancer-related death remain common [2] . The median overall survival (OS) of patients with advanced stage NSCLC with current standard chemotherapy is around 10 months [3] . Molecularly selected patients with activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation can be offered more durable survival with good quality of life with tyrosine kinase inhibitors [4, 5] .
Clearly new treatment options are necessary to further improve survival of patients with lung cancer. Immunotherapy for lung cancer has not been successful in the past. However, improved knowledge of tumor immunology, target antigens, and technical advances made it possible to develop promising therapies. This review will focus on recent results with these agents.
CANCER IMMUNOTHERAPY
There are many factors of dysfunction of the immune system in lung cancer patients, which we will not discuss further here (see e.g., [6] ). Cancer immunotherapy is any intervention in the immune system to correct this dysfunction and thereby treating the cancer. Recent advances in tumors other than lung cancer -such as the sipuleucel-T vaccine for castration-resistant prostate cancer [7] and ipilimumab for advanced melanoma [8] -have raised the expectations of immunotherapy for lung cancer.
Three different approaches can be distinguished. The first approach is a passive supply of antibodies targeting tumor-associated antigens leading to antibody-dependent cellular cytotoxicity (ADCC). This is more often quoted as targeted therapy with monoclonal antibodies (MAbs). The second approach is nonantigen-specific modulation of the immune system, such as the MAbs modulating T-cell activity, nowadays also called immune checkpoint inhibitors [9] . Discussion of these two approaches is beyond the scope of this review. The third approach is antigen-specific immunotherapy or therapeutic cancer vaccination. Tumor vaccines prime the immune system to produce antibodies, T-helper cells, and cytotoxic T cells against relevant tumorassociated antigens. To do so, a vaccine has to consist of immunogenic tumor-associated and preferably tumor-specific antigens [10] . Vaccines can be developed based on antigenic targets such as recombinant proteins, peptides, gangliosides, or whole tumor cells, always in combination with a strong adjuvant facilitating immune response. This review will focus on recent results that bring lung cancer vaccination closer to clinical practice (Table 1) 
FULL PROTEIN VACCINES
We will discuss the MAGE-A3 and TG4010 vaccines here [11
&&
,12] (Table 1) . Another example is the epidermal growth factor (EGF) vaccine CIMAvax [16] , that is coming from and currently approved in Cuba for advanced stage NSCLC, but for which no recent international or peer-reviewed data are available.
MAGE A3-vaccine
The melanoma-associated antigen A3 (MAGE-A3) is a promising target for therapeutic cancer vaccination. The antigen is almost exclusively expressed on tumor cells, not on normal adult tissues (except testis and placenta). Antigen expression is documented in 35% of early and 55% of advanced stages of NSCLC. Its function is unknown, but expression is associated with worse prognosis [17] . The vaccine is a full protein vaccine composed of a recombinant fusion protein (MAGE-A3 and protein D of Haemophilus influenzae) in combination with an immune response-enhancing adjuvant (ASO2 B ).
Results of the phase II randomized controlled trial (RCT) were reported recently [11 && ]. Patients with completely resected stage IB/II MAGE-A3-positive NSCLC were randomly assigned to either the vaccine (n ¼ 122) or placebo (n ¼ 60). Patients received induction with five vaccinations every 3 weeks, followed by a consolidation of eight administrations every 3 months. There was a positive trend in favor of MAGE-A3 treatment, though nonsignificant, potentially clinically relevant. An improvement in disease-free interval (DFI), disease-free survival (DFS), and OS was observed with hazard ratios of 0.75 (95% confidence interval, CI 0.46-1.23, P ¼ 0.254), 0.76 (95% CI 0.48-1.21, P ¼ 0.248), and 0.81 (95% CI 0.47-1.40, P ¼ 0.454), respectively, in favor of the vaccine. No significant toxicity was observed.
The MAGE-A3 as Adjuvant NSCLC Immunotherapy Trial (MAGRIT, NCT00480025) was initiated following these promising data. This large doubleblind, placebo-controlled phase III RCT evaluates the vaccine as an adjuvant therapy in MAGE-A3-positive patients with completely resected stage IB, II, or IIIA NSCLC. After standard care of surgery or surgery and adjuvant chemotherapy, patients will be treated with 13 intramuscular injections over a 27-month period. Recruitment was completed in December 2011 (2278 patients enrolled). DFS is the primary endpoint. First results are expected in 2014.
In advanced melanoma, a gene signature predictive of clinical activity of MAGE-A3 immunotherapy was identified. Based upon this experience, the same gene signature was studied as potential predictor of clinical benefit in patients with resected early stages of NSCLC from the phase II RCT. Actively treated gene signature-positive patients showed a favorable DFI compared with
KEY POINTS
Antigen-specific immunotherapy, that is, therapeutic tumor vaccination, is feasible, safe, and has promising results in recent randomized trials.
Postsurgical adjuvant MAGE A-3 vaccination is studied in the largest therapeutic trial ever done in NSCLC (MAGRIT).
After chemoradiotherapy for stage III NSCLC, L-BLP25 did not significantly improve OS in the phase III START trial, but a clinically relevant improvement in median OS of 10 months was seen in the large subgroup treated by concurrent chemoradiotherapy.
The whole tumor cell vaccine L-belagenpumatucel did not improve OS in the phase III study STOP, but promising findings were seen in some subgroups.
Predictive biomarkers will most probably be needed to identify the patients with significant OS benefits from antigen-specific immunotherapy. 
TG4010 vaccine
Mucinous glycoprotein-1 (MUC1) is a highly glycosylated transmembrane protein on the surface of epithelial cells [19] . MUC1 is often overexpressed and aberrantly glycosylated in cancer, which leads to impaired apoptosis, T-cell suppression, and worse prognosis. TG4010 is a vaccine based on a recombinant viral vector, a genetically altered Ankara virus, expressing both the MUC1 protein and interleukin 2 (IL2) [20] . IL2 is included, as it is able to reverse the immunosuppression by MUC1 [21] .
A phase II RCT enrolled 148 untreated patients with advanced stages (IIIB or IV) MUC1-positive NSCLC [12] . Patients received cisplatin-gemcitabine every 3 weeks up to six cycles or until disease progression, with or without TG4010. The vaccine was subcutaneously administered every week for 6 weeks and then every 3 weeks until progressive disease. Addition of TG4010 enhanced the effect of chemotherapy with a progression-free survival at 6 months of 43% (95% CI 33-54) in the vaccine group, and 35% (95% CI 26-45) in the placebo group. There was no significant difference in median OS (10.7 months in the vaccine group and 10.3 months in the placebo group). Further analysis showed that baseline level of activated natural killer (aNK) cells was a potential predictor of clinical vaccine activity. Median OS was significantly lower in patients with elevated baseline levels compared with patients showing normal levels of aNK cells (11.3 versus 18 months; P ¼ 0.020). Side-effects related to the vaccine were mild and most commonly included injection site reactions, abdominal pain, and fever. TIME, a phase IIB/III study of TG4010 immunotherapy in patients with stage IV NSCLC (NCT 01383148), will further evaluate the TG4010 vaccine in addition to first-line chemotherapy. This trial is currently still recruiting. Primary endpoints are the predictive value of aNK cells in the phase II part, and treatment effect on OS in the phase III part.
PEPTIDE VACCINES
A large phase III RCT with the peptide vaccine L-BLP25 was presented at the 2013 ASCO meeting [13 && ] (Table 1) .
L-BLP25 vaccine
The L-BLP25 vaccine (formerly called Stimuvax, more recently tecemotide) is a peptide vaccine based on a 25 amino acid sequence from the MUC1 protein in conjunction with an immunoadjuvant (monophosphoryl lipid A) in a liposomal delivery system [22] . The vaccine was studied in an open-label, phase II RCT with 171 patients with stage IIIB or IV NSCLC who had responded to or had stable disease after first-line therapy (chemoradiotherapy for stage III, chemotherapy for wet stage IIIB and stage IV). Patients were randomized to best supportive care (BSC) and L-BLP25 vaccination (n ¼ 88) or BSC alone (n ¼ 83) [23] . After pretreatment with cyclophosphamide (300 mg/m 2 ), L-BLP25 was given weekly during 8 weeks, followed by every 6 weeks until progression. Median OS was 17.4 months for the L-BLP25 group versus 13.0 months for controls (adjusted hazard ratio 0.739, 95% CI 0.509-1.073; P ¼ 0.112). Post-hoc analysis suggested that the benefit was confined to the subgroup of patients treated with chemoradiotherapy: their median OS was 30.6 versus 13.3 months for the L-BLP25 and control arms, respectively (adjusted hazard ratio 0.55, 95% CI 0.30-1.00; P ¼ 0.092). L-BLP25 vaccine is considered safe. Common adverse events in the vaccine group were flu-like symptoms and minor injection site reactions.
The consequential international phase III RCT START (Stimulating Targeted Antigenic Responses to NSCLC) compared maintenance therapy with either L-BLP25 vaccination (n ¼ 829) or placebo (n ¼ 410) in patients with stage III NSCLC who did not progress after sequential or concurrent chemoradiotherapy [13 && ]. The study drug was given weekly for 8 weeks followed by once every 6 weeks until progression. The primary endpoint -OS -was not significantly different between the vaccine and placebo group (25.6 and 22.3 months, adjusted hazard ratio 0.88, 95% CI 0.75-1.03; P ¼ 0.123). Interestingly, subgroup analysis revealed that the 829 patients treated with concurrent chemoradiotherapy had a remarkable 10-month improvement in OS: 30.8 versus 20.8 months (adjusted hazard ratio 0.78, 95% CI 0.64-0.95; P ¼ 0.016). In patients treated by sequential chemoradiotherapy, median OS was 19.4 months in the vaccine group versus 24.6 months in the placebo group (adjusted hazard ratio 1.12, 95% CI 0.87-1.44; P ¼ 0.38). Treatment was well tolerated with no difference in potential immune-related toxicities.
Another phase III trial, INSPIRE (Stimuvax Trial In Asian NSCLC Patients: Stimulating Immune Response), is still running in Asian patients with stage III unresectable NSCLC with a planned enrolment of 420 patients (NCT01015443).
GANGLIOSIDE VACCINES
Gangliosides -composed of glycosphingolipids with one or more linked sialic acids -are expressed on tumor cell surface. They are involved in cell-cell recognition, cell matrix adhesion, and cell differentiation. NeuGc-GM3 (Neu-glycosylated sialic acid containing ganglioside) is a variant of the normal Neu-acetylated form, and is identified almost exclusively in cancer cells, making it a good target for immunotherapy [24] .
Racotumomab (formerly IE10)
Racotumomab (formerly known as 1E10) is an antiidiotypic vaccine and induces a specific humoral and cellular response against NeuGc-GM3 [25, 26] .
Efficacy and safety of racotumomab are being evaluated in a prospective, multicenter phase II/III RCT (NCT01460472) in patients with stage IIIB or IV NSCLC achieving an objective response or stable disease after standard first-line treatment. After an induction of five doses every 2 weeks, patients continue with a maintenance phase of monthly vaccinations during a year. Afterwards, an open label extension was possible for patients receiving the active vaccine, continued beyond progression, unless start of second-line therapy, worsening of performance status, or unacceptable toxicity. An interim report on 176 patients was presented at the 2012 ESMO meeting [14] (Table 1 ). There was a slightly better median OS in favor of the vaccinated group. Patients whose clinical condition allowed them to receive five or more doses of racotumomab (77% of patient population) had a significantly better median OS (10.9 versus 6.9 months; P ¼ 0.002). The phase III part of the trial is ongoing.
WHOLE TUMOR CELL VACCINES
The results of a large phase III RCT with the allogeneic whole tumor cell belagenpumatucel-L were presented at the 2013 ESMO meeting [15 && ] (Table 1) .
Belagenpumatucel-L
This is an allogeneic cell vaccine derived from four NSCLC cell lines (two adenocarcinoma, one squamous cell carcinoma, and one large cell carcinoma), all exhibiting transforming growth factor b2 (TGF-b2) gene knockdown induced by antisense plasmid transfection. Elevated levels of TGF-b2 are linked to immunosuppression in cancer patients, and TGF-b2 levels are inversely correlated with prognosis in NSCLC [27] .
In an open label phase II dose comparison study, efficacy and safety of belagenpumatucel-L was investigated in 75 patients with stages II, III, and IV NSCLC. Patients were vaccinated with 1.25, 2.5, or 5.0 Â 10 7 cells/injection on a monthly or 2-monthly schedule up to 16 injections [28] . A dose-related OS was observed (2-year survival rate of 47% for patients receiving !2.5 Â 10 7 cells/ injection versus 18% of patients vaccinated with 1.25 Â 10 7 cells/injection). A partial response rate of 15% was achieved in patients with stages IIIB or IV (n ¼ 61) across all dose levels. Patients exhibiting both a cellular and humoral immune response to the vaccine (n ¼ 11) had improved OS compared with those (n ¼ 24) classified as immune-response negative: median OS 32.5 months (95% CI 25.2-39.8) versus 11.6 months (95% CI 5.6-17.6), respectively (P ¼ 0.011) [29] .
The results of the phase III RCT STOP (Survival Tumor-free, Overall, and Progression-free) were reported at the 2013 ESMO meeting [15 && ]. Patients with stages T3N2-IIIA, IIIB, and IV, without progression after first-line chemotherapy, were randomly assigned to intradermal belagenpumatucel-L (25 Â 106 cells in 0. 
CONCLUSION
In early stages of NSCLC, the MAGE-A3 vaccine showed a trend for improved DFI in the adjuvant setting after complete surgical resection. These data are to be validated in the larger phase III MAGRIT trial. The L-BLP25 vaccine in stage IIIB/IV NSCLC was associated with a better OS in the subset of patients with stage IIIB NSCLC treated by chemoradiotherapy. The phase III START trial, however, could not confirm a significant overall OS benefit, but in patients with stage III treated with concurrent chemoradiotherapy there was a quite impressive median OS benefit of 10 months.
In advanced NSCLC, the TG4010 vaccine resulted in a better progression-free survival when added to cisplatin-gemcitabine chemotherapy. These findings are studied in the ongoing phase III TIME trial. Patients vaccinated with racotumomab after standard first-line treatment for advanced stages of NSCLC showed a trend for better median OS at the interim analysis of the phase II/III trial and the study continues. The whole tumor cell vaccine L-belagenpumatucel had a dose-dependent effect on OS in open phase II trial. The phase III STOP trial did not significantly improve OS, but noteworthy treatment effects were noted in some subgroups.
For whatever approach, patient selection based on predictive biomarkers will be a major future challenge in antigen-specific immunotherapy. Several predictors of clinical response have been identified and undergo further prospective validation in ongoing phase III trials.
